Frantz Viral Therapeutics

Executive Summary

Frantz Viral Therapeutics (FVT) is a private biopharmaceutical company founded in 2019 as a joint venture between Georgetown University Medical Center and Frantz Medical Group. The company is developing non-surgical, self-administered treatments for human papillomavirus (HPV)-induced pre-cancers and cancers, leveraging proprietary artemisinin-related compounds. FVT's initial focus is on addressing high unmet needs in cervical, vulvar, anal, and oropharyngeal neoplasia. By offering a topical, patient-administered therapy, FVT aims to improve accessibility and reduce the burden of surgical interventions in low- and middle-income regions where HPV-related cancers are most prevalent.

Upcoming Catalysts (preview)

• TBDPhase 1/2 clinical trial data readout for lead candidate in cervical intraepithelial neoplasia (CIN)50% success
• TBDStrategic partnership or licensing agreement for global commercialization rights40% success
• TBDFDA guidance or Fast Track designation for lead program60% success